November 17, 2014 / 2:43 PM / 3 years ago

Valeant says can't justify matching Actavis bid for Allergan

1 Min Read

Nov 17 (Reuters) - Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Monday that the company can't justify matching Actavis Plc's $219 per share bid for Allergan Inc.

Allergan agreed to be bought by Actavis for $66 billion, more than $12 billion above the current value of a hostile bid by activist investor William Ackman and Valeant. (Reporting by Rod Nickel in Winnipeg, Manitoba; Editing by Bernadette Baum)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below